Immedica Pharma AB
Privately held: no public share price
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | EpilepsyDevelopmental and Epileptic Encephalopathies |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
December 2029 (1)
Est. primary completion 2029-12 · NCT05249556 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.